Skyhawk Therapeutics Expands its Agreement with Merck to Develop Novel Small Molecules Modulating RNA Splicing

 Skyhawk Therapeutics Expands its Agreement with Merck to Develop Novel Small Molecules Modulating RNA Splicing

Skyhawk Therapeutics Expands its Agreement with Merck to Develop Novel Small Molecules Modulating RNA Splicing

Shots::stohthShots:

  • Skyhawk will deploy its SkySTARTM platform to develop drug candidates targeting autoimmune and metabolic diseases and will receive an up front $600M/target while Merck get an option to exclusively license WW IP rights to candidates, discovered and developed under the agreement
  • If Merck exercises its option, Skyhawk will receive an option fees, milestones and royalties on sales of approved products resulting from the collaboration while Merck will be responsible for development & commercialization. The collaboration now covers neurodegeneration, oncology, autoimmunity, and metabolic diseases
  • The expanded collaboration in autoimmune and metabolic diseases reflects SkySTARTM platform’s ability to advance small molecules, addressing the unmet medical needs of patients

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Skyhawk

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post